Volume 19, Issue 1 (3-2025)
Qom Univ Med Sci J 2025, 19(1): 579-589 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zare O, Mohammadi Zeidi B, Nourollahpour Shiadeh M, Hamzeh M, Asadpoor H, Kiapour A. Pregnancy Complications and Maternal and Fetal Outcomes in Iranian Women With or Without A History of Sinopharm Vaccine Administration for COVID-19. Qom Univ Med Sci J 2025; 19 (1) : 3162.1
URL: http://journal.muq.ac.ir/article-1-4050-en.html
URL: http://journal.muq.ac.ir/article-1-4050-en.html
Ommolbanin Zare *1 
, Banafsheh Mohammadi Zeidi2 , Malihe Nourollahpour Shiadeh3 , Mahsa Hamzeh4 , Helya Asadpoor5 , Azaheh Kiapour5
, Banafsheh Mohammadi Zeidi2 , Malihe Nourollahpour Shiadeh3 , Mahsa Hamzeh4 , Helya Asadpoor5 , Azaheh Kiapour5
1- Department of Nursing and Midwifery, Bab.C., Islamic Azad University, Babol, Iran. , mahyazare@yahoo.com
2- Department of Nursing and Midwifery, To.C., Islamic Azad University, Tonekabon, Iran.
3- Health Research Centre, Mazandaran University of Medical Sciences, Sari, Iran.
4- Student Research Committee,Bab.C., Islamic Azad University, Babol, Iran.
5- Department of Statistics ,Bab.C., Islamic Azad University, Babol,Iran.
2- Department of Nursing and Midwifery, To.C., Islamic Azad University, Tonekabon, Iran.
3- Health Research Centre, Mazandaran University of Medical Sciences, Sari, Iran.
4- Student Research Committee,Bab.C., Islamic Azad University, Babol, Iran.
5- Department of Statistics ,Bab.C., Islamic Azad University, Babol,Iran.
Abstract: (689 Views)
Background and Objectives: Considering that the data related to the effects of inactivated COVID-19 vaccines such as Sinopharm is limited in low-income countries, this study aimed to investigate pregnancy complications and maternal and fetal outcomes in Iranian women with or without a history of Sinopharm vaccine administration for COVID-19.
Methods: This is a historical cohort study that was conducted on 500 vaccinated and non-vaccinated pregnant women referred to Imam Ali Hospital in Amol city, north of Iran, from July 2021 to June 2022. They were divided into two groups (250 vaccinated and 250 unvaccinated). The data were collected from their medical files.
Results: Pregnancy complications such as abortion (P=0.25), preterm delivery (P=0.69), premature rupture before labor (P=0.5), and meconium excretion (P=0.38) were not significantly different between the two groups. Maternal and fetal outcomes such as gestational age (P=0.27), type of delivery (P=0.6), fetal distress (P=0.3), neonatal respiratory distress (P=0.13), hospitalization in the neonatal unit (P=0.36), transfer to NICU (P=0.5), and congenital anomaly (P=0.5) were not significantly different between the two groups.
Conclusion: Vaccination with Sinopharm against COVID-19 is not associated with pregnancy complications or adverse maternal and fetal outcomes.
Methods: This is a historical cohort study that was conducted on 500 vaccinated and non-vaccinated pregnant women referred to Imam Ali Hospital in Amol city, north of Iran, from July 2021 to June 2022. They were divided into two groups (250 vaccinated and 250 unvaccinated). The data were collected from their medical files.
Results: Pregnancy complications such as abortion (P=0.25), preterm delivery (P=0.69), premature rupture before labor (P=0.5), and meconium excretion (P=0.38) were not significantly different between the two groups. Maternal and fetal outcomes such as gestational age (P=0.27), type of delivery (P=0.6), fetal distress (P=0.3), neonatal respiratory distress (P=0.13), hospitalization in the neonatal unit (P=0.36), transfer to NICU (P=0.5), and congenital anomaly (P=0.5) were not significantly different between the two groups.
Conclusion: Vaccination with Sinopharm against COVID-19 is not associated with pregnancy complications or adverse maternal and fetal outcomes.
Article number: 3162.1
Type of Study: Original Article |
Subject:
مامایی
Received: 2024/12/6 | Accepted: 2025/02/23 | Published: 2025/03/30
Received: 2024/12/6 | Accepted: 2025/02/23 | Published: 2025/03/30
References
1. Vitiello A, Ferrara F, Zovi A, Trama U, Boccellino M. Pregnancy and COVID-19, focus on vaccine and pharmacological treatment. J Reprod Immunol. 2022; 151:103630. [DOI:10.1016/j.jri.2022.103630] [PMID] [PMCID] [DOI:10.1016/j.jri.2022.103630]
2. Blakeway H, Prasad S, Kalafat E, Heath PT, Ladhani SN, Le Doare K, et sl. COVID-19 vaccination during pregnancy: coverage and safety. Am J Obstet Gynecol. 2022; 226(2):236.e1-14. [PMID] [DOI:10.1016/j.ajog.2021.08.007]
3. Garg I, Shekhar R, Sheikh AB, Pal S. COVID-19 vaccine in pregnant and lactating women: A review of existing evidence and practice guidelines. Infect Dis Rep. 2021; 13(3):685-99. [DOI:10.3390/idr13030064] [PMID] [PMCID] [DOI:10.3390/idr13030064]
4. Ai-ris YC, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA. 2021; 325(23):2370-80. [DOI:10.1001/jama.2021.7563] [DOI:10.1001/jama.2021.7563]
5. Fell DB, Dimitris MC, Hutcheon JA, Ortiz JR, Platt RW, Regan AK, et al. Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy. Vaccine. 2021; 39(14):1882-6. [DOI:10.1016/j.vaccine.2021.02.070] [PMID] [PMCID] [DOI:10.1016/j.vaccine.2021.02.070]
6. Yan Z, Yang M, Lai CL. COVID-19 Vaccinations: A comprehensive review of their safety and efficacy in special populations. Vaccines. 2021; 9(10):1097. [DOI:10.3390/vaccines9101097] [PMID] [PMCID] [DOI:10.3390/vaccines9101097]
7. de Freitas Paganoti C, Alkmin da Costa R, Papageorghiou AT, da Silva Costa F, Quintana SM, Graziela de Godoi L, et al. COVID-19 vaccines confer protection in hospitalized pregnant and postpartum women with severe COVID-19: A retrospective cohort study. Vaccines. 2022; 10(5):749. [DOI:10.3390/vaccines10050749] [PMID] [PMCID] [DOI:10.3390/vaccines10050749]
8. Ciapponi A, Berrueta M, P K Parker E, Bardach A, Mazzoni A, Anderson SA, et al. Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis. Vaccine. 2023; 41(25):3688-3700. [DOI:10.1016/j.vaccine.2023.03.038] [PMID] [PMCID] [DOI:10.1016/j.vaccine.2023.03.038]
9. Jeewandara C, Jayampathi KACS, Ranasinghe T, Aberathna IS, Gunasekara B, Danasekara S, et al. Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka. Plos Glob Public Health. 2022; 2(7):e0000607. [DOI:10.1371/journal.pgph.0000607] [PMID] [PMCID] [DOI:10.1371/journal.pgph.0000607]
10. Taghavi S, Dehdilani M, Dehdilani M. Comparison of pregnancy outcomes and neonatal complications between COVID-19-vaccinated and unvaccinated pregnant women in Tabriz, Iran. Immunopathologia Persa. 2023; 9(2):39520-. [DOI:10.34172/ipp.2023.39520] [DOI:10.34172/ipp.2023.39520]
11. Bleicher I, Kadour-Peero E, Sagi-Dain L, Sagi S. Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: Interim descriptive data from a prospective observational study. Vaccine. 2021; 39(44):6535-8. [DOI:10.1016/j.vaccine.2021.09.043] [PMID] [PMCID] [DOI:10.1016/j.vaccine.2021.09.043]
12. Theiler RN, Wick M, Mehta R, Weaver AL, Virk A, Swift M. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. Am J Obstet Gynecol MFM. 2021; 3(6):100467. [DOI:10.1016/j.ajogmf.2021.100467] [PMID] [PMCID] [DOI:10.1016/j.ajogmf.2021.100467]
13. Elsaddig M, Khalil A. Effects of the COVID pandemic on pregnancy outcomes. Best Pract Res Clin Obstet Gynaecol. 2021; 73:125-36. [DOI:10.1016/j.bpobgyn.2021.03.004] [PMID] [PMCID] [DOI:10.1016/j.bpobgyn.2021.03.004]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2008-1375
pISSN: 1735-7799
Email: journal[at]muq.ac.ir
j.mua.ac[at]gmail.com
